Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study

Moshe Talpaz,Josef Prchal,Lawrence Afrin,Murat Arcasoy,Solomon Hamburg,Jason Clark,Deanna Kornacki,Philomena Colucci,Srdan Verstovsek

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 7|浏览4

暂无评分

摘要

•Patients with myelofibrosis and low platelet counts received ruxolitinib•Ruxolitinib was initiated at 5 mg BID and could be titrated up to 15 mg BID•52 of 66 patients (78.8%) completed the first 24 weeks of ruxolitinib treatment•Improvement in spleen volume and symptoms were greatest with ruxolitinib 10 mg BID•Median platelet and hemoglobin levels were generally stable through week 24

查看译文

关键词

Janus kinase inhibitor,Myeloproliferative neoplasm,Spleen volume,Thrombocytopenia,Total Symptom Score

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study